Why the study?
Fluid overload and central sleep apnea are highly prevalent in patients with HF, prompting an assessment of the effects of acetazolamide therapy on acid/base balance and apnea indexes.
Does acetazolamide therapy improve acid/base balance and apnea indexes in patients with heart failure?
Does acetazolamide therapy improve acid/base balance and apnea indexes in patients with heart failure?
Acetazolamide therapy in heart failure patients is associated with significant reductions in serum pH, increased natriuresis, and improvements in apnea indexes.
Acetazolamide may aid apnea management in HF; extends pooled evidence on its acid-base and natriuretic effects.
BACKGROUND AND OBJECTIVES: Fluid overload and central sleep apnea are highly prevalent in patients with heart failure (HF). We performed this meta-analysis to assess the effects of acetazolamide therapy on acid/base balance and apnea indexes. METHODS: A literature search was conducted using EMBASE, MEDLINE, and Cochrane Database from inception through 18 November 2017 to identify studies evaluating the use of acetazolamide in HF. Study results were analyzed using a random effects model. The protocol for this systematic review is registered with PROSPERO (International Prospective Register of Systematic Reviews; no. CRD42017065401). RESULTS: = 0.20, 0.75 and 0.59 for analysis of the changes in pH, pCO₂, and serum bicarbonate levels with use of acetazolamide in HF patients. CONCLUSION: Our study demonstrates significant reduction in serum pH, increase in natriuresis, and improvements in apnea indexes with use of acetazolamide among HF patients.
No takes yet. Share an insight, caveat, or question.
Wongboonsin et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: